WHO Immunization Implementation Guide
0.1.0 - CI Build
WHO Immunization Implementation Guide
0.1.0 - CI Build
WHO Immunization Implementation Guide, published by World Health Organization (WHO). This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/WorldHealthOrganization/smart-immunizations and changes regularly. See the Directory of published versions
| Draft as of 2024-05-30 |
{
"resourceType" : "CodeSystem",
"id" : "IMMZ.D1",
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>This case-insensitive code system <code>http://smart.who.int/ig/smart-immunizations/CodeSystem/IMMZ.D1</code> defines the following codes:</p><table class=\"codes\"><tr><td style=\"white-space:nowrap\"><b>Code</b></td><td><b>Display</b></td><td><b>Definition</b></td></tr><tr><td style=\"white-space:nowrap\">DE109<a name=\"IMMZ.D1-DE109\"> </a></td><td>Birth dose</td><td>Indicates if the client received a dose within 24 hours of birth. Whether a birth dose is counted as part of the primary series will depend on the antigen.</td></tr><tr><td style=\"white-space:nowrap\">DE103<a name=\"IMMZ.D1-DE103\"> </a></td><td>Type of dose</td><td>The type of dose in a series that the client received</td></tr><tr><td style=\"white-space:nowrap\">DE104<a name=\"IMMZ.D1-DE104\"> </a></td><td>Primary series</td><td>Indicates that the client received the primary vaccination series of a product/antigen. This is also applicable for antigens with one dose.</td></tr><tr><td style=\"white-space:nowrap\">DE105<a name=\"IMMZ.D1-DE105\"> </a></td><td>Dose 0</td><td>Indicates that the client received a dose of a product/ antigen within 24 hours of birth. This dose is not a part of the primary vaccination series.</td></tr><tr><td style=\"white-space:nowrap\">DE106<a name=\"IMMZ.D1-DE106\"> </a></td><td>Supplementary dose</td><td>Indicates that the client received a supplementary dose of a product/antigen</td></tr><tr><td style=\"white-space:nowrap\">DE107<a name=\"IMMZ.D1-DE107\"> </a></td><td>Booster dose</td><td>Indicates that the client received booster dose of a product/antigen</td></tr><tr><td style=\"white-space:nowrap\">DE8<a name=\"IMMZ.D1-DE8\"> </a></td><td>Completed the primary vaccination series</td><td>Indicates if the client has completed the primary vaccination series of a product/antigen. If the client has not yet completed their primary series, it means they may be expected to receive more doses to complete their vaccination regimen for the respective product/antigen.</td></tr><tr><td style=\"white-space:nowrap\">DE102<a name=\"IMMZ.D1-DE102\"> </a></td><td>Completed the booster series</td><td>Indicates if the client has completed the booster series of a product/antigen</td></tr><tr><td style=\"white-space:nowrap\">DE81<a name=\"IMMZ.D1-DE81\"> </a></td><td>Date when primary vaccination series was completed</td><td>The date when the client completed the primary vaccination series (per product/antigen)</td></tr><tr><td style=\"white-space:nowrap\">DE10<a name=\"IMMZ.D1-DE10\"> </a></td><td>HIV status</td><td>The current human immunodeficiency virus (HIV) status of the client</td></tr><tr><td style=\"white-space:nowrap\">DE11<a name=\"IMMZ.D1-DE11\"> </a></td><td>HIV-positive</td><td>The client is known to be HIV positive</td></tr><tr><td style=\"white-space:nowrap\">DE12<a name=\"IMMZ.D1-DE12\"> </a></td><td>HIV-negative</td><td>The client is known to be HIV negative</td></tr><tr><td style=\"white-space:nowrap\">DE13<a name=\"IMMZ.D1-DE13\"> </a></td><td>Unknown</td><td>The client's HIV status is unknown</td></tr><tr><td style=\"white-space:nowrap\">DE15<a name=\"IMMZ.D1-DE15\"> </a></td><td>Preterm birth</td><td>The infant was preterm; the mother gave birth to the infant when gestational age was less than 37 weeks</td></tr><tr><td style=\"white-space:nowrap\">DE16<a name=\"IMMZ.D1-DE16\"> </a></td><td>Immunocompromised</td><td>The client is known to be immunocompromised. This means the client has a weakened immune system and having a reduced ability to fight infections and other diseases</td></tr><tr><td style=\"white-space:nowrap\">DE17<a name=\"IMMZ.D1-DE17\"> </a></td><td>Currently on ART</td><td>The client is currently receiving antiretroviral therapy (ART)</td></tr><tr><td style=\"white-space:nowrap\">DE84<a name=\"IMMZ.D1-DE84\"> </a></td><td>Type of TB infection test performed</td><td>The type of TB infection test performed</td></tr><tr><td style=\"white-space:nowrap\">DE85<a name=\"IMMZ.D1-DE85\"> </a></td><td>IGRA</td><td>Interferon-gamma release assay (IGRA)</td></tr><tr><td style=\"white-space:nowrap\">DE86<a name=\"IMMZ.D1-DE86\"> </a></td><td>TST</td><td>Tuberculin skin test (TST)</td></tr><tr><td style=\"white-space:nowrap\">DE87<a name=\"IMMZ.D1-DE87\"> </a></td><td>TB infection test result</td><td>Records the result of the TB infection test</td></tr><tr><td style=\"white-space:nowrap\">DE88<a name=\"IMMZ.D1-DE88\"> </a></td><td>Positive</td><td>Test result was positive</td></tr><tr><td style=\"white-space:nowrap\">DE89<a name=\"IMMZ.D1-DE89\"> </a></td><td>Negative</td><td>Test result was negative</td></tr><tr><td style=\"white-space:nowrap\">DE93<a name=\"IMMZ.D1-DE93\"> </a></td><td>Immunologically stable</td><td>The client is living with HIV and is immunologically stable with CD4 count or percentage above a minimum as defined in the HIV guidelines</td></tr><tr><td style=\"white-space:nowrap\">DE94<a name=\"IMMZ.D1-DE94\"> </a></td><td>Clinically well</td><td>The client is living with HIV and is clinically well, as defined in HIV guidelines and WHO clinical staging</td></tr><tr><td style=\"white-space:nowrap\">DE29<a name=\"IMMZ.D1-DE29\"> </a></td><td>Birth weight in grams</td><td>Represents the client's birth weight value measures in grams</td></tr><tr><td style=\"white-space:nowrap\">DE35<a name=\"IMMZ.D1-DE35\"> </a></td><td>Type of polio dose</td><td>The type of the polio vaccine dose administered to the client</td></tr><tr><td style=\"white-space:nowrap\">DE36<a name=\"IMMZ.D1-DE36\"> </a></td><td>IPV</td><td>Inactivated poliovirus vaccine (IPV)</td></tr><tr><td style=\"white-space:nowrap\">DE37<a name=\"IMMZ.D1-DE37\"> </a></td><td>bOPV</td><td>Bivalent oral poliovirus vaccine (bOPV)</td></tr><tr><td style=\"white-space:nowrap\">DE92<a name=\"IMMZ.D1-DE92\"> </a></td><td>Severely immunosuppressed</td><td>The client is known to be severely immunosuppressed</td></tr><tr><td style=\"white-space:nowrap\">DE49<a name=\"IMMZ.D1-DE49\"> </a></td><td>ART start date</td><td>The date on which the client started or restarted antiretroviral therapy (ART)</td></tr><tr><td style=\"white-space:nowrap\">DE96<a name=\"IMMZ.D1-DE96\"> </a></td><td>High risk of pneumococcal infection</td><td>The client is at high risk for pneumococcal infection because of underlying medical conditions (i.e. HIV infection or sickle-cell disease)</td></tr><tr><td style=\"white-space:nowrap\">DE52<a name=\"IMMZ.D1-DE52\"> </a></td><td>Type of JE dose</td><td>The type of Japanese encephalitis (JE) vaccine dose administered to the client</td></tr><tr><td style=\"white-space:nowrap\">DE53<a name=\"IMMZ.D1-DE53\"> </a></td><td>Inactivated Vero cell-derived vaccine</td><td>Inactivated Vero cell-derived Japanese encephalitis (JE) vaccine type</td></tr><tr><td style=\"white-space:nowrap\">DE54<a name=\"IMMZ.D1-DE54\"> </a></td><td>Live attenuated vaccine</td><td>Live attenuated Japanese encephalitis (JE) vaccine type</td></tr><tr><td style=\"white-space:nowrap\">DE55<a name=\"IMMZ.D1-DE55\"> </a></td><td>Live recombinant vaccine</td><td>Live recombinant Japanese encephalitis (JE) vaccine type</td></tr><tr><td style=\"white-space:nowrap\">DE56<a name=\"IMMZ.D1-DE56\"> </a></td><td>Type of TBE dose</td><td>The type of tick-borne encephalitis (TBE) vaccine dose administered</td></tr><tr><td style=\"white-space:nowrap\">DE57<a name=\"IMMZ.D1-DE57\"> </a></td><td>FSME-Immun</td><td>FSME-Immun vaccine product, which is an inactivated whole-virus vaccine for tick-borne encephalitis (TBE)</td></tr><tr><td style=\"white-space:nowrap\">DE58<a name=\"IMMZ.D1-DE58\"> </a></td><td>Encepur</td><td>Encepur vaccine product, which is an inactivated viral vaccine for tick-borne encephalitis (TBE)</td></tr><tr><td style=\"white-space:nowrap\">DE59<a name=\"IMMZ.D1-DE59\"> </a></td><td>TBE-Moscow</td><td>TBE-Moscow vaccine product, which is a vaccine for tick-borne encephalitis (TBE)</td></tr><tr><td style=\"white-space:nowrap\">DE60<a name=\"IMMZ.D1-DE60\"> </a></td><td>EnceVir</td><td>EnceVir vaccine product, which is a vaccine for tick-borne encephalitis (TBE)</td></tr><tr><td style=\"white-space:nowrap\">DE61<a name=\"IMMZ.D1-DE61\"> </a></td><td>Type of typhoid dose</td><td>The type of typhoid vaccine dose administered to the client</td></tr><tr><td style=\"white-space:nowrap\">DE62<a name=\"IMMZ.D1-DE62\"> </a></td><td>Typbar-TCV</td><td>Typbar-TCV vaccine</td></tr><tr><td style=\"white-space:nowrap\">DE63<a name=\"IMMZ.D1-DE63\"> </a></td><td>ViPS</td><td>Vi polysaccharide (ViPS) vaccine</td></tr><tr><td style=\"white-space:nowrap\">DE64<a name=\"IMMZ.D1-DE64\"> </a></td><td>Ty21a</td><td>Ty21a vaccine</td></tr><tr><td style=\"white-space:nowrap\">DE65<a name=\"IMMZ.D1-DE65\"> </a></td><td>Type of cholera dose</td><td>The type of cholera vaccine dose administered to the client</td></tr><tr><td style=\"white-space:nowrap\">DE66<a name=\"IMMZ.D1-DE66\"> </a></td><td>WC vaccine</td><td>Killed whole cell (WC) only cholera vaccine</td></tr><tr><td style=\"white-space:nowrap\">DE67<a name=\"IMMZ.D1-DE67\"> </a></td><td>WC-rBS vaccine</td><td>Vaccine contains a mixture of the recombinant B subunit (rBS) of cholera toxin plus killed whole cell (WC)</td></tr><tr><td style=\"white-space:nowrap\">DE68<a name=\"IMMZ.D1-DE68\"> </a></td><td>Type of meningococcal dose</td><td>The type of meningococcal vaccine dose administered to the client</td></tr><tr><td style=\"white-space:nowrap\">DE69<a name=\"IMMZ.D1-DE69\"> </a></td><td>MenA conjugate vaccine (5µg)</td><td>Monovalent serogroup A (MenA) conjugate vaccine (5µg) vaccine</td></tr><tr><td style=\"white-space:nowrap\">DE70<a name=\"IMMZ.D1-DE70\"> </a></td><td>Monovalent MenC conjugate</td><td>Monovalent MenC conjugate vaccine</td></tr><tr><td style=\"white-space:nowrap\">DE71<a name=\"IMMZ.D1-DE71\"> </a></td><td>Quadrivalent conjugate</td><td>Quadrivalent conjugate (A,C,W135,Y-D and A,C,W135,Y-CRM) vaccines</td></tr><tr><td style=\"white-space:nowrap\">DE97<a name=\"IMMZ.D1-DE97\"> </a></td><td>Polysaccharide vaccine</td><td>Polysaccharide vaccines not including polysaccharide-protein conjugate vaccines</td></tr><tr><td style=\"white-space:nowrap\">DE72<a name=\"IMMZ.D1-DE72\"> </a></td><td>Age in months when client received first meningococcal dose</td><td>The age in months when client received their first meningococcal dose</td></tr><tr><td style=\"white-space:nowrap\">DE73<a name=\"IMMZ.D1-DE73\"> </a></td><td>Type of hepatitis A dose</td><td>The type of hepatitis A vaccine dose administered to the client</td></tr><tr><td style=\"white-space:nowrap\">DE74<a name=\"IMMZ.D1-DE74\"> </a></td><td>Live attenuated hepatitis A vaccine</td><td>Live attenuated hepatitis A vaccine</td></tr><tr><td style=\"white-space:nowrap\">DE75<a name=\"IMMZ.D1-DE75\"> </a></td><td>Inactivated hepatitis A vaccine</td><td>Inactivated hepatitis A vaccine</td></tr><tr><td style=\"white-space:nowrap\">DE99<a name=\"IMMZ.D1-DE99\"> </a></td><td>Type of hepatitis B dose</td><td>The type of hepatitis B vaccine dose administered to the client</td></tr><tr><td style=\"white-space:nowrap\">DE100<a name=\"IMMZ.D1-DE100\"> </a></td><td>Hepatitis B monovalent vaccine</td><td>Hepatitis B monovalent vaccine</td></tr><tr><td style=\"white-space:nowrap\">DE101<a name=\"IMMZ.D1-DE101\"> </a></td><td>Hepatitis B combination vaccine</td><td>Hepatitis B combination vaccine</td></tr><tr><td style=\"white-space:nowrap\">DE76<a name=\"IMMZ.D1-DE76\"> </a></td><td>VNA level</td><td>Vaccine-induced neutralizing (VNA) antibody level. It is a measured as a serum antibody concentration amount observed from the result of the concentrated, purified cell culture and embryonated egg-based rabies vaccines (CCEEV)</td></tr><tr><td style=\"white-space:nowrap\">DE98<a name=\"IMMZ.D1-DE98\"> </a></td><td>Risk of occupational exposure to rabies virus</td><td>Professional at risk of occupational exposure to rabies virus, particularly animal health-care workers. Also considered for medical professionals who regularly provide care to persons with rabies.</td></tr><tr><td style=\"white-space:nowrap\">DE77<a name=\"IMMZ.D1-DE77\"> </a></td><td>Dengue serostatus</td><td>Indicates the result of a serological test determining whether the client has antibodies against the dengue virus</td></tr><tr><td style=\"white-space:nowrap\">DE110<a name=\"IMMZ.D1-DE110\"> </a></td><td>Positive</td><td>The client has detectable antibodies against the dengue virus, suggesting past exposure or vaccination</td></tr><tr><td style=\"white-space:nowrap\">DE111<a name=\"IMMZ.D1-DE111\"> </a></td><td>Negative</td><td>The client does not have detectable antibodies, indicating no previous exposure or vaccination against the dengue virus</td></tr><tr><td style=\"white-space:nowrap\">DE112<a name=\"IMMZ.D1-DE112\"> </a></td><td>Unknown</td><td>The client's dengue serostatus is unknown</td></tr></table></div>"
},
"url" : "http://smart.who.int/ig/smart-immunizations/CodeSystem/IMMZ.D1",
"version" : "0.1.0",
"name" : "IMMZ_D1",
"title" : "IMMZ.D1 CodeSystem for Data Elements",
"status" : "draft",
"experimental" : false,
"date" : "2024-05-30T21:26:16+00:00",
"publisher" : "World Health Organization (WHO)",
"contact" : [
{
"name" : "World Health Organization (WHO)",
"telecom" : [
{
"system" : "url",
"value" : "https://www.who.int"
}
]
}
],
"description" : "CodeSystem for IMMZ.D1 Data Elements",
"jurisdiction" : [
{
"coding" : [
{
"system" : "http://unstats.un.org/unsd/methods/m49/m49.htm",
"code" : "001"
}
]
}
],
"caseSensitive" : false,
"content" : "complete",
"count" : 65,
"concept" : [
{
"code" : "DE109",
"display" : "Birth dose",
"definition" : "Indicates if the client received a dose within 24 hours of birth. Whether a birth dose is counted as part of the primary series will depend on the antigen."
},
{
"code" : "DE103",
"display" : "Type of dose",
"definition" : "The type of dose in a series that the client received"
},
{
"code" : "DE104",
"display" : "Primary series",
"definition" : "Indicates that the client received the primary vaccination series of a product/antigen. This is also applicable for antigens with one dose."
},
{
"code" : "DE105",
"display" : "Dose 0",
"definition" : "Indicates that the client received a dose of a product/ antigen within 24 hours of birth. This dose is not a part of the primary vaccination series."
},
{
"code" : "DE106",
"display" : "Supplementary dose",
"definition" : "Indicates that the client received a supplementary dose of a product/antigen"
},
{
"code" : "DE107",
"display" : "Booster dose",
"definition" : "Indicates that the client received booster dose of a product/antigen"
},
{
"code" : "DE8",
"display" : "Completed the primary vaccination series",
"definition" : "Indicates if the client has completed the primary vaccination series of a product/antigen. If the client has not yet completed their primary series, it means they may be expected to receive more doses to complete their vaccination regimen for the respective product/antigen."
},
{
"code" : "DE102",
"display" : "Completed the booster series",
"definition" : "Indicates if the client has completed the booster series of a product/antigen"
},
{
"code" : "DE81",
"display" : "Date when primary vaccination series was completed",
"definition" : "The date when the client completed the primary vaccination series (per product/antigen)"
},
{
"code" : "DE10",
"display" : "HIV status",
"definition" : "The current human immunodeficiency virus (HIV) status of the client"
},
{
"code" : "DE11",
"display" : "HIV-positive",
"definition" : "The client is known to be HIV positive"
},
{
"code" : "DE12",
"display" : "HIV-negative",
"definition" : "The client is known to be HIV negative"
},
{
"code" : "DE13",
"display" : "Unknown",
"definition" : "The client's HIV status is unknown"
},
{
"code" : "DE15",
"display" : "Preterm birth",
"definition" : "The infant was preterm; the mother gave birth to the infant when gestational age was less than 37 weeks"
},
{
"code" : "DE16",
"display" : "Immunocompromised",
"definition" : "The client is known to be immunocompromised. This means the client has a weakened immune system and having a reduced ability to fight infections and other diseases"
},
{
"code" : "DE17",
"display" : "Currently on ART",
"definition" : "The client is currently receiving antiretroviral therapy (ART)"
},
{
"code" : "DE84",
"display" : "Type of TB infection test performed",
"definition" : "The type of TB infection test performed"
},
{
"code" : "DE85",
"display" : "IGRA",
"definition" : "Interferon-gamma release assay (IGRA)"
},
{
"code" : "DE86",
"display" : "TST",
"definition" : "Tuberculin skin test (TST)"
},
{
"code" : "DE87",
"display" : "TB infection test result",
"definition" : "Records the result of the TB infection test"
},
{
"code" : "DE88",
"display" : "Positive",
"definition" : "Test result was positive"
},
{
"code" : "DE89",
"display" : "Negative",
"definition" : "Test result was negative"
},
{
"code" : "DE93",
"display" : "Immunologically stable",
"definition" : "The client is living with HIV and is immunologically stable with CD4 count or percentage above a minimum as defined in the HIV guidelines"
},
{
"code" : "DE94",
"display" : "Clinically well",
"definition" : "The client is living with HIV and is clinically well, as defined in HIV guidelines and WHO clinical staging"
},
{
"code" : "DE29",
"display" : "Birth weight in grams",
"definition" : "Represents the client's birth weight value measures in grams"
},
{
"code" : "DE35",
"display" : "Type of polio dose",
"definition" : "The type of the polio vaccine dose administered to the client"
},
{
"code" : "DE36",
"display" : "IPV",
"definition" : "Inactivated poliovirus vaccine (IPV)"
},
{
"code" : "DE37",
"display" : "bOPV",
"definition" : "Bivalent oral poliovirus vaccine (bOPV)"
},
{
"code" : "DE92",
"display" : "Severely immunosuppressed",
"definition" : "The client is known to be severely immunosuppressed"
},
{
"code" : "DE49",
"display" : "ART start date",
"definition" : "The date on which the client started or restarted antiretroviral therapy (ART)"
},
{
"code" : "DE96",
"display" : "High risk of pneumococcal infection",
"definition" : "The client is at high risk for pneumococcal infection because of underlying medical conditions (i.e. HIV infection or sickle-cell disease)"
},
{
"code" : "DE52",
"display" : "Type of JE dose",
"definition" : "The type of Japanese encephalitis (JE) vaccine dose administered to the client"
},
{
"code" : "DE53",
"display" : "Inactivated Vero cell-derived vaccine",
"definition" : "Inactivated Vero cell-derived Japanese encephalitis (JE) vaccine type"
},
{
"code" : "DE54",
"display" : "Live attenuated vaccine",
"definition" : "Live attenuated Japanese encephalitis (JE) vaccine type"
},
{
"code" : "DE55",
"display" : "Live recombinant vaccine",
"definition" : "Live recombinant Japanese encephalitis (JE) vaccine type"
},
{
"code" : "DE56",
"display" : "Type of TBE dose",
"definition" : "The type of tick-borne encephalitis (TBE) vaccine dose administered"
},
{
"code" : "DE57",
"display" : "FSME-Immun",
"definition" : "FSME-Immun vaccine product, which is an inactivated whole-virus vaccine for tick-borne encephalitis (TBE)"
},
{
"code" : "DE58",
"display" : "Encepur",
"definition" : "Encepur vaccine product, which is an inactivated viral vaccine for tick-borne encephalitis (TBE)"
},
{
"code" : "DE59",
"display" : "TBE-Moscow",
"definition" : "TBE-Moscow vaccine product, which is a vaccine for tick-borne encephalitis (TBE)"
},
{
"code" : "DE60",
"display" : "EnceVir",
"definition" : "EnceVir vaccine product, which is a vaccine for tick-borne encephalitis (TBE)"
},
{
"code" : "DE61",
"display" : "Type of typhoid dose",
"definition" : "The type of typhoid vaccine dose administered to the client"
},
{
"code" : "DE62",
"display" : "Typbar-TCV",
"definition" : "Typbar-TCV vaccine"
},
{
"code" : "DE63",
"display" : "ViPS",
"definition" : "Vi polysaccharide (ViPS) vaccine"
},
{
"code" : "DE64",
"display" : "Ty21a",
"definition" : "Ty21a vaccine"
},
{
"code" : "DE65",
"display" : "Type of cholera dose",
"definition" : "The type of cholera vaccine dose administered to the client"
},
{
"code" : "DE66",
"display" : "WC vaccine",
"definition" : "Killed whole cell (WC) only cholera vaccine"
},
{
"code" : "DE67",
"display" : "WC-rBS vaccine",
"definition" : "Vaccine contains a mixture of the recombinant B subunit (rBS) of cholera toxin plus killed whole cell (WC)"
},
{
"code" : "DE68",
"display" : "Type of meningococcal dose",
"definition" : "The type of meningococcal vaccine dose administered to the client"
},
{
"code" : "DE69",
"display" : "MenA conjugate vaccine (5µg)",
"definition" : "Monovalent serogroup A (MenA) conjugate vaccine (5µg) vaccine"
},
{
"code" : "DE70",
"display" : "Monovalent MenC conjugate",
"definition" : "Monovalent MenC conjugate vaccine"
},
{
"code" : "DE71",
"display" : "Quadrivalent conjugate",
"definition" : "Quadrivalent conjugate (A,C,W135,Y-D and A,C,W135,Y-CRM) vaccines"
},
{
"code" : "DE97",
"display" : "Polysaccharide vaccine",
"definition" : "Polysaccharide vaccines not including polysaccharide-protein conjugate vaccines"
},
{
"code" : "DE72",
"display" : "Age in months when client received first meningococcal dose",
"definition" : "The age in months when client received their first meningococcal dose"
},
{
"code" : "DE73",
"display" : "Type of hepatitis A dose",
"definition" : "The type of hepatitis A vaccine dose administered to the client"
},
{
"code" : "DE74",
"display" : "Live attenuated hepatitis A vaccine",
"definition" : "Live attenuated hepatitis A vaccine"
},
{
"code" : "DE75",
"display" : "Inactivated hepatitis A vaccine",
"definition" : "Inactivated hepatitis A vaccine"
},
{
"code" : "DE99",
"display" : "Type of hepatitis B dose",
"definition" : "The type of hepatitis B vaccine dose administered to the client"
},
{
"code" : "DE100",
"display" : "Hepatitis B monovalent vaccine",
"definition" : "Hepatitis B monovalent vaccine"
},
{
"code" : "DE101",
"display" : "Hepatitis B combination vaccine",
"definition" : "Hepatitis B combination vaccine"
},
{
"code" : "DE76",
"display" : "VNA level",
"definition" : "Vaccine-induced neutralizing (VNA) antibody level. It is a measured as a serum antibody concentration amount observed from the result of the concentrated, purified cell culture and embryonated egg-based rabies vaccines (CCEEV)"
},
{
"code" : "DE98",
"display" : "Risk of occupational exposure to rabies virus",
"definition" : "Professional at risk of occupational exposure to rabies virus, particularly animal health-care workers. Also considered for medical professionals who regularly provide care to persons with rabies."
},
{
"code" : "DE77",
"display" : "Dengue serostatus",
"definition" : "Indicates the result of a serological test determining whether the client has antibodies against the dengue virus"
},
{
"code" : "DE110",
"display" : "Positive",
"definition" : "The client has detectable antibodies against the dengue virus, suggesting past exposure or vaccination"
},
{
"code" : "DE111",
"display" : "Negative",
"definition" : "The client does not have detectable antibodies, indicating no previous exposure or vaccination against the dengue virus"
},
{
"code" : "DE112",
"display" : "Unknown",
"definition" : "The client's dengue serostatus is unknown"
}
]
}